BirdoTech: Delivering a Resilient Supply Chain for Drug Development
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

BirdoTech: Delivering a Resilient Supply Chain for Drug Development

Follow BirdoTech on :

Branden Lee, Director of Business Development, BirdoTechBranden Lee, Director of Business Development
Amidst the public health and economic maelstrom brought on by a global pandemic, supply chains in all aspects of businesses are being re-examined. Suddenly, the world is confronted with the need for more global coordination—not less. Sponsor companies are re-prioritizing projects and CRO/CDMOs are learning to remain agile. Deeper alignments of functions and capacity are necessary to navigate this uncertain environment. Those who can remain resilient and forward-looking will become indispensable partners. Shanghai-based BirdoTech is one such CRO/CDMO. In just a few years, BirdoTech has supported clinical projects from research stage to manufacturing. Their success comes from their unparalleled focus on listening to their partners and proactively solving problems. “BirdoTech specializes in small-molecules process R&D, supplying pharmaceutical raw materials and active pharmaceutical intermediates (API),” explains Branden Lee, Director of Business Development. Their ability to take laboratory-scale reactions and scale up to tons in short lead-time is the primary reason why sponsor companies want to work with them.

BirdoTech offers full-time equivalent (FTE) medicinal chemistry services supporting early drug discovery research. With their in-house process chemistry team, synthetic routes are optimized to address raw material costs, environmental safety, and overall reliability for supply resilience. They operate well-equipped state of the art synthetic chemistry laboratories allowing their chemists to explore and scale-up complex chemical reactions. BirdoTech’s teams of over 300 chemists support clients’ hit identification, lead generation (LG), and lead optimization (LO) programs in record-setting pace. Aside from the chemistry throughput, BirdoTech excels in communications and flexibility. They understand the need for letting the science drive the projects. More importantly, they recognize that their work does not exist in a silo. Almost all their discovery projects are coordinated with in vitro and in vivo data, DMPK, and toxicology studies from outside parties to advance their client’s project forward. Assistance with patent preparation is also routinely conducted.

BirdoTech specializes in small-molecules process R&D, supplying pharmaceutical raw materials and active pharmaceutical intermediates (API)

Communications is the critical glue to the execution of a project. BirdoTech’s project management team is US-based and is staffed by experienced pharmaceutical chemists. This arrangement allows for more efficient communications with their US and European clients around the clock. Their project managers bring their experiences from the pharma industry. They understand the western culture, the expectations, and the complex regulations between different regions of the world. Oftentimes, stakeholders on all sides must juggle among shifting targets, compressing timelines, and staying within budgets. Regardless of the expectations, they work tirelessly to deliver. Their responsibilities encompass scientific, business, and logistics. Some recent challenges have included tariffs and reduced flight capacities during import/export.

Recognizing the importance of quality, time, and cost in relation to bringing a drug onto the market, BirdoTech can tailor process development strategies, regardless of whether a project is in the preclinical stage or is ready for commercialization. BirdoTech provides consistent supplies of bulk API in commercial quantities. Their QC team develops all the necessary protocols for technology transfer and manufacturing. Then their QA team track and document the batch-to-batch consistency for product release. They understand that their facility can be and do get audited by government agencies and sponsors regularly. Therefore, they are committed to maintaining the highest standards of regulatory and environmental compliance. Their facilities are designed to safely handle complex, multi-step organic synthesis in kilograms to multiple metric ton quantities.

BirdoTech is a well-funded organization with R&D sites in three locations. This provides a breadth of expertise in different areas of research. Recent areas of additions have included photoredox chemistry, flow chemistry toward screening and manufacturing, and peptide chemistry. They also recognized the importance of investing in people. Team members excel at their trained skill sets; they must also be invested in their client’s success. The culture at BirdoTech is—constantly be learning—and oftentimes, learning comes from their client interactions. The company understands the urgency to move quickly and advance clinical assets to commercial manufacturing. BirdoTech is helping build a healthier future for all and is poised to become a preeminent CDMO.
Share this Article:

Company
BirdoTech

Headquarters
Shanghai, China

Management
Branden Lee, Director of Business Development

Description
A CRO that specializes in the R&D of pharmaceutical raw materials and active pharmaceutical intermediates. BirdoTech offers full-time equivalent (FTE) medicinal chemistry services supporting early drug discovery research. With their in-house process chemistry team, synthetic routes are optimized to address raw material costs, environmental safety, and overall reliability for supply resilience. BirdoTech can tailor process development strategies, regardless of whether a project is in the preclinical stage or is ready for commercialization

BirdoTech